Tech Company Financing Transactions
Cerenis Therapeutics Funding Round
Cerenis Therapeutics secured a $53.5 million Series B financing round on 11/13/2006. Backers included TVM Capital, Alta Partners and EDF Ventures.
Transaction Overview
Company Name
Announced On
11/13/2006
Transaction Type
Venture Equity
Amount
$53,500,000
Round
Series B
Investors
TVM Capital (Lead Investor) (Alexandra Goll)
Proceeds Purpose
The Series B funding will support Cerenis'
clinical development programs in cardiovascular and metabolic diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
PO Box 861
Lakeland, MI 48143
USA
Lakeland, MI 48143
USA
Phone
Website
Email Address
Overview
Cerenis therapeutics: an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies (good cholesterol) for treating cardiovascular and metabolic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jean-Louis Dasseux
Chief Financial Officer
Cyril Tupin
VP - Bus. Development
Constance Keyserling
Browse more venture capital transactions:
Prev: 11/13/2006: Firefly Energy venture capital transaction
Next: 11/13/2006: Ceptaris Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs